Paul Breillat

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Venues

Lupus

Nature communications

Annals of the rheumatic diseases

Science (New York, N.Y.)

This page only lists publications with an associated author ORCID identifier.

Publications

Olivier Kosmider, Céline Possémé, Marie Temple, Aurélien Corneau, Francesco Carbone, Eugénie Duroyon, Paul Breillat, Twinu-Wilson Chirayath, Bénédicte Oulès, Pierre Sohier, Marine Luka, Camille Gobeaux, Estibaliz Lazaro, Roderau Outh, Guillaume Le Guenno, François Lifermann, Marie Berleur, Melchior Le Mene, Chloé Friedrich, Cédric Lenormand, Thierry Weitten, Vivien Guillotin, Barbara Burroni, Jeremy Boussier, Lise Willems, Selim Aractingi, Léa Dionet, Pierre-Louis Tharaux, Béatrice Vergier, Pierre Raynaud, Hang-Korng Ea, Mickaël Mathieu Ménager, Darragh Duffy, Benjamin Terrier
VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation. Nature communications 15 (1) (2024)
Olivier Kosmider, Céline Possémé, Marie Temple, Aurélien Corneau, Francesco Carbone, Eugénie Duroyon, Paul Breillat, Twinu-Wilson Chirayath, Bénédicte Oulès, Pierre Sohier, Marine Luka, Camille Gobeaux, Estibaliz Lazaro, Roderau Outh, Guillaume Le Guenno, François Lifermann, Marie Berleur, Melchior Le Mene, Chloé Friedrich, Cédric Lenormand, Thierry Weitten, Vivien Guillotin, Barbara Burroni, Jeremy Boussier, Lise Willems, Selim Aractingi, Léa Dionet, Pierre-Louis Tharaux, Béatrice Vergier, Pierre Raynaud, Hang-Korng Ea, Mickaël Mathieu Ménager, Darragh Duffy, Benjamin Terrier
VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation. Nature communications 15 (1) (2024)
Olivier Kosmider, Céline Possémé, Marie Temple, Aurélien Corneau, Francesco Carbone, Eugénie Duroyon, Paul Breillat, Twinu-Wilson Chirayath, Bénédicte Oulès, Pierre Sohier, Marine Luka, Camille Gobeaux, Estibaliz Lazaro, Roderau Outh, Guillaume Le Guenno, François Lifermann, Marie Berleur, Melchior Le Mene, Chloé Friedrich, Cédric Lenormand, Thierry Weitten, Vivien Guillotin, Barbara Burroni, Jeremy Boussier, Lise Willems, Selim Aractingi, Léa Dionet, Pierre-Louis Tharaux, Béatrice Vergier, Pierre Raynaud, Hang-Korng Ea, Mickaël Mathieu Ménager, Darragh Duffy, Benjamin Terrier
VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation. Nature communications 15 (1) (2024)
Paul Breillat, Alexis Mathian, Flore Rozenberg, Amélie Dutheil, Annick Barbaud, Zahir Amoura, François Chasset
Is there an increased risk of severe COVID-19 among patients with systemic lupus erythematosus treated with anifrolumab? Lupus 32 (3) (2023)
Paul Breillat, Alexis Mathian, Flore Rozenberg, Amélie Dutheil, Annick Barbaud, Zahir Amoura, François Chasset
Is there an increased risk of severe COVID-19 among patients with systemic lupus erythematosus treated with anifrolumab? Lupus (2023)
Paul Breillat, Alexis Mathian, Flore Rozenberg, Amélie Dutheil, Annick Barbaud, Zahir Amoura, François Chasset
Is there an increased risk of severe COVID-19 among patients with systemic lupus erythematosus treated with anifrolumab? Lupus 32 (3) (2023)
Paul Breillat, Alexis Mathian, Flore Rozenberg, Amélie Dutheil, Annick Barbaud, Zahir Amoura, François Chasset
Is there an increased risk of severe COVID-19 among patients with systemic lupus erythematosus treated with anifrolumab? Lupus 32 (3) (2023)
Paul Breillat, Alexis Mathian, Flore Rozenberg, Amélie Dutheil, Annick Barbaud, Zahir Amoura, François Chasset
Is there an increased risk of severe COVID-19 among patients with systemic lupus erythematosus treated with anifrolumab? Lupus (2023)
Paul Breillat, Alexis Mathian, Flore Rozenberg, Amélie Dutheil, Annick Barbaud, Zahir Amoura, François Chasset
Is there an increased risk of severe COVID-19 among patients with systemic lupus erythematosus treated with anifrolumab? Lupus (2023)
Paul Breillat, Kuberaka Mariampillai, Paul Legendre, Pauline Martins, Bertrand Dunogue, Jean Luc Charuel, Makoto Miyara, Claire Goulvestre, Romain Paule, Helene Vanquaethem, Felix Ackermann, Olivier Benveniste, Hilario Nunes, Luc Mouthon, Yves Allenbach, Yurdagul Uzunhan
Anti-PM-Scl antibodies positive patients encompass three different groups with distinct prognosis. Rheumatology (Oxford, England) (2022)
Alexis Mathian, Paul Breillat, Karim Dorgham, Paul Bastard, Caroline Charre, Raphael Lhote, Paul Quentric, Quentin Moyon, Alice-Andrée Mariaggi, Suzanne Mouries-Martin, Clara Mellot, François Anna, Julien Haroche, Fleur Cohen-Aubart, Delphine Sterlin, Noël Zahr, Adrian Gervais, Tom Le Voyer, Lucy Bizien, Quentin Amiot, Micheline Pha, Miguel Hié, Francois Chasset, Hans Yssel, Makoto Miyara, Pierre Charneau, Pascale Ghillani-Dalbin, Jean-Laurent Casanova, Flore Rozenberg, Zahir Amoura, Guy Gorochov
Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α. Annals of the rheumatic diseases 81 (12) (2022)
Jérôme Hadjadj, Nader Yatim, Laura Barnabei, Aurélien Corneau, Jeremy Boussier, Nikaïa Smith, Hélène Péré, Bruno Charbit, Vincent Bondet, Camille Chenevier-Gobeaux, Paul Breillat, Nicolas Carlier, Rémy Gauzit, Caroline Morbieu, Frédéric Pène, Nathalie Marin, Nicholas Roche, Tali-Anne Szwebel, Sarah Hélène Merkling, Jean-Marc Treluyer, David Veyer, Luc Mouthon, Catherine Blanc, Pierre-Louis Tharaux, Flore Rozenberg, Alain Fischer, Darragh Duffy, Frédéric Rieux-Laucat, Solen Kerneis, Benjamin Terrier
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science (New York, N.Y.) 369 (6504) (2020)

Paul Breillat.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Paul Breillat